Effects on calcium phosphate homeostasis after sodium-glucose cotransporter 2 inhibitor in patients with advanced chronic kidney disease and type 2 diabetes mellitus
Authors' conclusion
SGLT2i can effectively slow down the progression of phosphate retention in advanced CKD with T2DM.
Study context
- Population
- Patients with T2D and chronic kidney disease (CKD) stage G3b-5ND, 1 January 2015 through 31 December 2021propensity score 1:3
- Participants
- 1,450 vs 4,350
- Exposure
- SGLT2i vs control
- SGLT2in = 1,450
- Controln = 4,350reference
- Outcome
- Changes in phosphate level
- Follow-up
- 12 months
Methodological detailsobservational, propensity score assignment at 1:3 ratio
- Observational
- Propensity score assignment at 1:3 ratio
Main finding
As reported in the abstract
Absolute change in phosphate · 12th month
SGLT2i
−0.01
± 0.28 · mmol/L
Control
+ 0.14
± 0.34 · mmol/L
P for both < 0.001
Observational data: associations, not effects.
Further findings
Increase in proportion with high phosphate
| Outcome | SGLT2i | Control | B | P value |
|---|---|---|---|---|
| Percentage change in phosphate · 12th month | −0.74 % ± 25.56 | + 10.88 ± 28.15 % | P for both < 0.001 | |
| Longitudinal phosphate (generalized estimating equation) | −0.039 | P < 0.001 |
Original publication
Effects on calcium phosphate homeostasis after sodium-glucose cotransporter 2 inhibitor in patients with advanced chronic kidney disease and type 2 diabetes mellitus. Diabetes Res Clin Pract. Published 14 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →